3D imaging and artificial intelligence to predict cancer therapy effectiveness
Total Trials
1
As Lead Sponsor
0
As Collaborator
Total Enrollment
324
NCT06349642
Predicting Response to Immune Checkpoint Inhibitors Across Solid Tumors Using a Live Tumor Diagnostic Platform
Phase: N/A
Role: Collaborator
Start: Apr 24, 2024
Completion: May 31, 2027
Loading map...